NEW DELHI: Pune-based Krsnaa Diagnostics, an built-in diagnostics supplier, introduced plans to amass almost 24% stake in start-up Apulki Healthcare for unique rights to offer diagnostics companies.
Apulki Healthcare, integrated in 2022, is engaged in establishing, working and sustaining hospitals, specializing in oncology and cardiology, primarily beneath the public-private partnership mode, says an organization assertion.
The acquisition might be accomplished inside the subsequent three months.
Beneath this collaboration, Krsnaa Diagnostics will change into the unique diagnostics associate for Apulki’s state-of-the-art most cancers and cardiac hospitals for the subsequent 30+ years. This ensures Krsnaa’s sustained management within the high-growth oncology and cardiac diagnostic segments, with entry to Apulki’s deliberate community of 10+ hospitals throughout India.
By providing a complete suite of cutting-edge diagnostic applied sciences—together with MRI, PET CT, Cardiac CT, and Superior Pathology—out there 24×7 beneath one roof, Krsnaa and Apulki will present seamless, world-class diagnostic companies for sufferers present process most cancers and cardiac therapy.
